NASDAQ:SUPNSupernus Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Supernus Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $18.81 +0.24 (+1.29 %) (As of 04/10/2020 07:18 AM ET) Add Compare Share Today's Range$18.34Now: $18.81▼$19.2250-Day Range$14.45MA: $18.01▼$24.3652-Week Range$13.12Now: $18.81▼$39.04Volume491,563 shsAverage Volume739,748 shsMarket Capitalization$988.09 millionP/E Ratio8.91Dividend YieldN/ABeta1.49 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Supernus Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine. The company's product candidates comprise SPN-812, a viloxazine hydrochloride, which is in Phase III clinical trial that is used for the treatment of attention deficit hyperactivity disorder (ADHD); SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with ADHD; SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression; SPN-604 extended release oxcarbazepine for bipolar; and SPN-817 that is in phase I clinical trial for treating epilepsy. The company markets its products through wholesalers and distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingSupernus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $43.80, Supernus Pharmaceuticals has a potential upside of 132.9% from its current price of $18.81.Amount of Analyst CoverageSupernus Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 3.1 Community Rank Outperform VotesSupernus Pharmaceuticals has received 439 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSupernus Pharmaceuticals has received 270 “underperform” votes. (Add your “underperform” vote.)Community SentimentSupernus Pharmaceuticals has received 61.92% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Supernus Pharmaceuticals and other stocks. Vote “Outperform” if you believe SUPN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SUPN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSupernus Pharmaceuticals does not currently pay a dividend.Dividend GrowthSupernus Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Supernus Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.57% of the stock of Supernus Pharmaceuticals is held by insiders.Percentage Held by Institutions97.63% of the stock of Supernus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Supernus Pharmaceuticals are expected to grow by 11.90% in the coming year, from $1.26 to $1.41 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Supernus Pharmaceuticals is 8.91, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 11.30.Price to Earnings Ratio vs. SectorThe P/E ratio of Supernus Pharmaceuticals is 8.91, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 15.73.Price to Book Value per Share RatioSupernus Pharmaceuticals has a P/B Ratio of 1.66. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.85 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:SUPN Previous Symbol CUSIP86845910 CIK1356576 Webhttp://www.supernus.com/ Phone301-838-2500Debt Debt-to-Equity Ratio0.63 Current Ratio2.94 Quick Ratio2.78Price-To-Earnings Trailing P/E Ratio8.91 Forward P/E Ratio14.93 P/E GrowthN/A Sales & Book Value Annual Sales$392.76 million Price / Sales2.52 Cash Flow$2.53 per share Price / Cash Flow7.43 Book Value$11.35 per share Price / Book1.66Profitability EPS (Most Recent Fiscal Year)$2.10 Net Income$113.06 million Net Margins28.78% Return on Equity20.98% Return on Assets10.38%Miscellaneous Employees448 Outstanding Shares52,530,000Market Cap$988.09 million Next Earnings Date5/5/2020 (Estimated) OptionableOptionable Receive SUPN News and Ratings via Email Sign-up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:SUPN Rates by TradingView Supernus Pharmaceuticals (NASDAQ:SUPN) Frequently Asked Questions How has Supernus Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Supernus Pharmaceuticals' stock was trading at $16.15 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SUPN shares have increased by 16.5% and is now trading at $18.81. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Supernus Pharmaceuticals? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Supernus Pharmaceuticals in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Supernus Pharmaceuticals. When is Supernus Pharmaceuticals' next earnings date? Supernus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Supernus Pharmaceuticals. How were Supernus Pharmaceuticals' earnings last quarter? Supernus Pharmaceuticals Inc (NASDAQ:SUPN) announced its quarterly earnings data on Tuesday, February, 25th. The specialty pharmaceutical company reported $0.62 EPS for the quarter, topping the Zacks' consensus estimate of $0.57 by $0.05. The specialty pharmaceutical company earned $100.45 million during the quarter, compared to the consensus estimate of $107.27 million. Supernus Pharmaceuticals had a net margin of 28.78% and a return on equity of 20.98%. View Supernus Pharmaceuticals' earnings history. What guidance has Supernus Pharmaceuticals issued on next quarter's earnings? Supernus Pharmaceuticals updated its FY 2020 After-Hours earnings guidance on Tuesday, February, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $360-390 million, compared to the consensus revenue estimate of $407.73 million. What price target have analysts set for SUPN? 6 equities research analysts have issued 12 month target prices for Supernus Pharmaceuticals' stock. Their forecasts range from $23.00 to $63.00. On average, they expect Supernus Pharmaceuticals' share price to reach $43.80 in the next year. This suggests a possible upside of 132.9% from the stock's current price. View analysts' price targets for Supernus Pharmaceuticals. What are Wall Street analysts saying about Supernus Pharmaceuticals stock? Here are some recent quotes from research analysts about Supernus Pharmaceuticals stock: 1. According to Zacks Investment Research, "Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. " (3/3/2020) 2. Mizuho analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and are adjusting our price target to $18 from $3, based on the following factors: (1) adjustment to base year; (2) adjustment ot fully diluted share count; (3) accounting for the 1 for 15 reverse split; and (4) increasing our discount rate to 30% from our usual 15%, to account for increased perceived risk in developing drugs for both pancreatic cancer and AML. We note that there is still a relatively large delta between the current share price and our target, which is now also largely attributable to the low number of shares outstanding post-reverse split." (8/7/2019) Has Supernus Pharmaceuticals been receiving favorable news coverage? Media coverage about SUPN stock has been trending very negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Supernus Pharmaceuticals earned a news impact score of -3.3 on InfoTrie's scale. They also assigned news articles about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutSupernus Pharmaceuticals. Are investors shorting Supernus Pharmaceuticals? Supernus Pharmaceuticals saw a decrease in short interest in the month of March. As of March 13th, there was short interest totaling 5,581,700 shares, a decrease of 10.4% from the February 27th total of 6,230,000 shares. Based on an average daily volume of 653,000 shares, the days-to-cover ratio is currently 8.5 days. Currently, 11.0% of the shares of the stock are short sold. View Supernus Pharmaceuticals' Current Options Chain. Who are some of Supernus Pharmaceuticals' key competitors? Some companies that are related to Supernus Pharmaceuticals include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT). What other stocks do shareholders of Supernus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Supernus Pharmaceuticals investors own include NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), AbbVie (ABBV), GW Pharmaceuticals PLC- (GWPH), Exelixis (EXEL), Netflix (NFLX), Cara Therapeutics (CARA), Corcept Therapeutics (CORT) and Pfizer (PFE). Who are Supernus Pharmaceuticals' key executives? Supernus Pharmaceuticals' management team includes the following people: Mr. Jack A. Khattar, Founder, Pres, CEO, Sec. & Director (Age 58)Mr. Gregory S. Patrick, Sr. VP & CFO (Age 68)Dr. Padmanabh P. Bhatt, Chief Scientific Officer & Sr. VP of Intellectual Property (Age 62)Dr. Stefan K. F. Schwabe, Chief Medical Officer and Exec. VP of R&D (Age 67)Dr. Todd Horich M.B.A., Ph.D., VP of Marketing What is Supernus Pharmaceuticals' stock symbol? Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN." Who are Supernus Pharmaceuticals' major shareholders? Supernus Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include State of Alaska Department of Revenue (0.09%). Company insiders that own Supernus Pharmaceuticals stock include Gregory S Patrick, Jack A Khattar, Padmanabh P Bhatt, Stefan KF Schwabe and Victor Vaughn. View institutional ownership trends for Supernus Pharmaceuticals. Which major investors are buying Supernus Pharmaceuticals stock? SUPN stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. View insider buying and selling activity for Supernus Pharmaceuticals. How do I buy shares of Supernus Pharmaceuticals? Shares of SUPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Supernus Pharmaceuticals' stock price today? One share of SUPN stock can currently be purchased for approximately $18.81. How big of a company is Supernus Pharmaceuticals? Supernus Pharmaceuticals has a market capitalization of $988.09 million and generates $392.76 million in revenue each year. The specialty pharmaceutical company earns $113.06 million in net income (profit) each year or $2.10 on an earnings per share basis. Supernus Pharmaceuticals employs 448 workers across the globe. View additional information about Supernus Pharmaceuticals. What is Supernus Pharmaceuticals' official website? The official website for Supernus Pharmaceuticals is http://www.supernus.com/. How can I contact Supernus Pharmaceuticals? Supernus Pharmaceuticals' mailing address is 1550 E GUDE DR, ROCKVILLE MD, 20850. The specialty pharmaceutical company can be reached via phone at 301-838-2500 or via email at [email protected] This page was last updated on 4/10/2020 by MarketBeat.com StaffFeatured Article: Outstanding Shares and The Effect on Share Price
